US FDA Bans More Products from Ranbaxy
January 24, 2014 2:17 PM EST
The U.S. Food and Drug Administration said on Thursday it has banned more products from drugmaker Ranbaxy Laboratories (RANB.NS) from entering the United States due to manufacturing violations.
A Ranbaxy office building in Mohali
The FDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa, India "to prevent substandard quality products from reaching U.S. consumers."
The move follows an FDA inspection of the facility which identified significant violations of good manufacturing practices.
Staff at the Toansa facility were found to have retested raw materials and other ingredients after the items failed analytical testing "in order to produce acceptable findings," and did not report or investigate the failures, the FDA said.
The ban is the latest in a series of measures taken by the FDA to keep substandard products made by Ranbaxy out of the U.S. market. The FDA previously banned products from the company's facilities in Paonta Sahib, Dewas and Mohali as part of a consent decree designed to ensure compliance with good manufacturing practices.
The FDA's latest move means Ranbaxy's products are all but entirely banned from the United States.
Most Popular Slideshows
Join the Conversation
- Google HTC Nexus 9 Tablet October 24 Launch Date Benefits Many
- Apple iPhone 6 vs. OnePlus One: With Invitation-Only Model Rested, OnePlus One Can Be A Real Threat To iPhone 6
- Galaxy Note 4 vs Nexus 6: Which Smartphone Dominates
- MH 370 Search In Ocean To Intensify With Hi Tech Ships Joining The Plane Hunt From October
- New Windows OS Is Not Windows 9, Microsoft To Launch Windows 10 As New OS Build
- Samsung Aware Of Gap Issue On Galaxy Note 4, Mentions It As Important Manufacturing Feature In Note 4 User Manual
- Airstrikes Against ISIS Has Claimed Innocent Lives In Syria, Dubbed ‘Ineffective’ By Jihadi Fighters, US Military To Ask For More Spending Money